Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

@article{Aponte2007SafetyOT,
  title={Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial},
  author={John J. Aponte and Pedro Aide and Montse Renom and In{\'a}cio Mandomando and Quique Bassat and Jahit Sacarlal and Maria N{\'e}lia Manaca and Sarah Lafuente and Arnoldo Barbosa and Amanda Jane Leach and Marc Lievens and Johan Vekemans and Betuel Siga{\'u}que and Marie Claude Dubois and M A Demoiti{\'e} and Marla Sillman and Barbara Savarese and John G. McNeil and Eusebio Macete and W. Ripley Ballou and Joe D. Cohen and Pedro Lu{\'i}s Alonso},
  journal={The Lancet},
  year={2007},
  volume={370},
  pages={1543-1551}
}

Figures and Tables from this paper

Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial

The RTS,S/AS02D malaria vaccine administered to young infants has a good safety profile and remains efficacious over 14 months, and a strong association between anti-CS antibodies and risk of clinical malaria has been described for the first time.

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

The acceptable safety profile and good tolerability of RTS,S/AS02D in combination with EPI vaccines previously reported from month 0 to 9 was confirmed over a 20 month surveillance period in this infant population.

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.

The use of the RTS,S/AS02D vaccine in infants had a promising safety profile, did not interfere with the immunologic responses to coadministered EPI antigens, and reduced the incidence of malaria infection.

Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children

The malaria vaccine candidate, RTS,S/AS01E, showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months and showed an acceptable safety profile in children living in a malaria-endemic area in East Africa.

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area

Both candidate malaria vaccines had a good safety profile and were well tolerated over a 12 month surveillance period and both produced strong anti-HBs responses.

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa

This pivotal phase III study of the RTS,S/AS01 candidate malaria vaccine in African children will provide efficacy and safety data to fulfil regulatory requirements, together with data on a broad range of endpoints that will facilitate the evaluation of the public health impact of the vaccine and will aid policy and implementation decisions.

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon

RTS,S/AS01E proved similarly as well tolerated and immunogenic as RTS, S/AS02D, completing an essential step in the age de-escalation process within the R TS,S clinical development plan.
...

References

SHOWING 1-10 OF 14 REFERENCES

Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial

The data show that the RTS, S/AS02D is safe, well tolerated, and demonstrates non-inferiority (defined as upper limit of the 95% confidence interval of the anti-CS GMT ratio of RTS), a pediatric formulation of GlaxoSmithKline Biologicals' current malaria candidate vaccine.

Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique

The RTS,S/AS02A candidate malaria vaccine has been shown to be safe and immunogenic in previous studies in adults and staggered dose‐escalation studies in children in The Gambia, and genetic features and the intensity of malaria transmission may modify the safety and immune response.

Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial.

IPTi with SP has been shown to moderately reduce the incidence of clinical malaria in Mozambican infants without evidence of rebound after stopping the intervention or of interactions with EPI vaccines.

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

Overall protective efficacy of RTS,S/SBAS2 was 41% (95% confidence interval, 22%-56%; P=.0006).

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

A recombinant vaccine based on fusion of the circumsporozoite protein and HBsAg plus a potent adjuvant can protect against experimental challenge with P. falciparum malaria.

Sustained use of insecticide-treated curtains is not associated with greater circulation of drug-resistant malaria parasites, or with higher risk of treatment failure among children with uncomplicated malaria in Burkina Faso.

In this setting, ITC use was not associated with increased circulation of parasites resistant to standard antimalarial drugs, or with a greater risk of treatment failure among children less than 5 years of age.

The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania.

  • G. HuttonF. Tediosi
  • Political Science
    The American journal of tropical medicine and hygiene
  • 2006
Although the vaccine price still determines most of the total delivery costs, the analysis shows that other costs are relevant and should be taken into account before marketing the vaccine and planning its inclusion into the EPI.